A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Inclusion Criteria:

• Adequately clear ocular media, adequate pupillary dilation, and fixation to allowacquisition of good quality fundus imaging

• GA that resides completely within the fundus autofluorescence (FAF) imaging field

• Presence of hyperautofluorescence of either banded or diffuse pattern adjacent tothe GA area on FAF

• Study eye has early treatment of diabetic retinopathy study (ETDRS) best-correctedvisual acuity (BCVA) score as follows:

• Part 1A: 19 to 48 letters inclusively

• Part 1B: > 19 letters

• Part 2: ≥ 24 letters

• Total GA lesion size must be as follows:

• Parts 1A and 1B: ≥ 1.25 square millimeter (mm^2) and ≤ 17.5 mm^2 )

• Part 2: ≥ 2.5 mm^2 and ≤ 17.5 mm^2

Exclusion Criteria:

Ocular Exclusion Criteria for the Study Eye:

• Aphakic or pseudophakic with intraocular lens outside of the capsular bag

• Previous laser photocoagulation or IVT anti-vascular endothelial growth factor (VEGF) for CNV, diabetic macular edema (DME), retinal vein occlusion (RVO), orproliferative diabetic retinopathy

Ocular Exclusion Criteria for the Non-Study Eye:

• Non-functioning non-study eye, defined as either: BCVA of hand motion or worse and/or no physical presence of eye

Ocular Exclusion Criteria for Both Eyes:

• Macular atrophy in either eye due to causes other than AMD

• Evidence of prior or active CNV

• Prior treatment with any approved therapy for GA (Syfovre, Izervay) in either eyefor Part 1A and Part 2. For Part 1B, prior treatment with any approved therapy forGA (Syfovre, Izervay) in the study eye ≤ 20 weeks prior to Day 1